Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Akoya Biosciences Inc. (AKYA) Insider Trading Activity
Healthcare • Medical Instruments & Supplies • 330 employees
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Total Value
-$19,658.00
Total Shares
532,150
Average Trade Value
-$1,404.14
Most Active Insider
Mc Kelligon Brian
Total Activity: $35,765
Largest Single Transaction
$13,459
by Mc Kelligon Brian on Mar 1, 2025
30-Day Activity
9 Transactions
Volume: 36,600 shares
Value: $59,658
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
CFO
Officer
|
Mar 1, 2025 | 3,594 | $5,858 | 264,634 (-1.4%) | Payment of Exercise Price | |
|
Chief Business Officer
Officer
|
Mar 1, 2025 | 3,594 | $5,858 | 289,520 (-1.2%) | Payment of Exercise Price | |
|
Chief Legal Officer
Officer
|
Mar 1, 2025 | 3,594 | $5,858 | 179,272 (-2.0%) | Payment of Exercise Price | |
|
Chief Legal Officer
Officer
|
Mar 1, 2025 | 3,851 | $6,277 | 182,866 (-2.1%) | Payment of Exercise Price | |
|
Chief Clinical Officer
Officer
|
Mar 1, 2025 | 1,283 | $2,091 | 208,975 (-0.6%) | Payment of Exercise Price | |
|
Chief Clinical Officer
Officer
|
Mar 1, 2025 | 2,567 | $4,184 | 206,408 (-1.2%) | Payment of Exercise Price | |
|
President and CEO
Director, Officer
|
Mar 1, 2025 | 7,550 | $12,307 | 435,933 (-1.7%) | Payment of Exercise Price | |
|
President and CEO
Director, Officer
|
Mar 1, 2025 | 8,257 | $13,459 | 427,676 (-1.9%) | Payment of Exercise Price | |
|
Chief Business Officer
Officer
|
Mar 1, 2025 | 2,310 | $3,765 | 293,114 (-0.8%) | Payment of Exercise Price | |
|
Chief Business Officer
Officer
|
Nov 19, 2024 | 87,500 | $10,000 | 295,424 (+29.6%) | Grant | |
|
CFO
Officer
|
Nov 19, 2024 | 87,500 | $10,000 | 268,228 (+32.6%) | Grant | |
|
Chief Clinical Officer
Officer
|
Nov 19, 2024 | 87,500 | $0 | 210,258 (+41.6%) | Grant | |
|
President and CEO
Director, Officer
|
Nov 19, 2024 | 218,750 | $10,000 | 443,483 (+49.3%) | Grant | |
|
Chief Legal Officer
Officer
|
Nov 19, 2024 | 87,500 | $10,000 | 186,717 (+46.9%) | Grant |